(SeaPRwire) –   /NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

SASKATOON, SK, March 20, 2026 – ZYUS Life Sciences Corporation (the “Company“) (TSXV: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management, is pleased to announce the completion of the first tranche (the “First Tranche“) of its non-brokered private placement (the “Offering“) of units (each a “Unit“), as previously disclosed on February 24, 2026. The size of the Offering has been adjusted from a maximum of C$7,000,000 (for up to 11,111,111 Units) – as outlined in the February 24, 2026 news release – to a maximum of C$1,100,000 (for up to 1,746,031 Units).

In the First Tranche of the Offering, the Company issued 451,269 Units at a price of C$0.63 per Unit, generating gross proceeds of approximately C$284,300. The Company expects to close an additional tranche in the near future.

Each Unit consists of one common share of the Company (a “Common Share“) and one-half (½) of one Common Share purchase warrant (each whole Common Share purchase warrant, a “Warrant“). Each Warrant entitles the holder to acquire one Common Share at a price of C$0.85 for a period of twenty-four months from the date of issuance. Proceeds from the Offering will be used for general corporate purposes and working capital. No finder’s fees were paid in connection with the Offering.

The Units were offered via private placement, utilizing exemptions from prospectus requirements under applicable securities laws. All securities issued under the First Tranche are subject to a hold period expiring July 21, 2026, in line with applicable securities laws and the policies of the TSX Venture Exchange (the “TSXV“). The Offering has received conditional approval from the TSXV and remains subject to the exchange’s final acceptance.

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities laws. They may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws, or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States.

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a clinical stage life sciences company focused on the development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguard its innovative therapies and enhance shareholder value. ZYUS is unwaveringly committed to obtaining regulatory approval for non-opioid-based pharmaceutical solutions in pursuit of a transformational impact on patients’ lives. For additional information, visit www.zyus.com or follow the company on X @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains statements that may constitute “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian and United States securities legislation. Readers are cautioned against placing undue reliance on such forward-looking content. Forward-looking statements and information are often identified by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “possible” or statements that certain events or conditions “may”, “will”, “could”, or “should” occur. These statements include those related to the proposed Offering and are based on current expectations and assumptions that involve a number of risks, which could cause actual results to differ—including materially—from those anticipated by the Company and described in the forward-looking statements in this release.

These risks and uncertainties include, but are not limited to: the Company’s planned use of Offering proceeds; the risk that the Offering will not be completed; the risk that regulatory approval for the Offering may not be obtained; the risk that funds from the Offering will be insufficient to support the Company’s operations; and the risk that without completing the Offering, the Company will be unable to fund its operations and obligations. No assurance can be given that any of the events outlined in the forward-looking statements will transpire or occur.

The forward-looking statements in this release are made as of the date of publication and are expressly qualified in their entirety by this cautionary note. The Company does not undertake any obligation to update or revise these forward-looking statements publicly—whether due to new information, future events, or otherwise—except as required by applicable securities laws. While management believes the assumptions underlying these forward-looking statements are reasonable, the Company cannot assure investors that actual results will align with them. These forward-looking statements are dated as of today and are fully qualified by this cautionary statement.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE ZYUS Life Sciences Corporation